Study study type PathologyT1T0Patientssample sizesROB Results

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
abiraterone plus ADT
LATITUDE, 2019
  NCT01715285
RCTmetastatic, hormone-sensitive prostate cancerandrogen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily)androgen-deprivation therapy plus dual placebospatients with newly diagnosed, metastatic, castration-sensitive prostate cancer-/-NA
conclusif
  • demonstrated 38 % decrease in deaths (OS) (PE)
STAMPEDE abiraterone, 2017
  NCT00268476
RCTmetastatic, hormone-sensitive prostate cancerabiraterone acetate (1000 mg daily) and prednisolone (5 mg daily)ADT aloneProstate Cancer Not Previously Treated with Hormone Therapy-/-NA
conclusif
  • demonstrated 37 % decrease in deaths (OS) (PE)
apalutamide plus ADT
TITAN, 2019
  NCT02489318
RCTmetastatic, hormone-sensitive prostate cancer525 / 527NA
conclusif
  • demonstrated 33 % decrease in deaths (OS) (PE)
docetaxel plus ADT
NCI E3805 (Scott), 2017
  NCT00309985
RCTmetastatic, hormone-sensitive prostate cancer397 / 393NA
conclusif
  • demonstrated 39 % decrease in deaths (OS) (PE)
STAMPEDE docetaxel, 2016
  NCT00268476
metastatic, hormone-sensitive prostate cancer-/-NA
suggested
  • suggested 22 % decrease in deaths (OS)
GETUG-AFU 15, 2013
  NCT00104715
RCTmetastatic, hormone-sensitive prostate cancerdocetaxel and androgen-deprivation therapy (ADT)androgen-deprivation therapy (ADT) alonepatients with metastatic non-castrate prostate cancer-/-NA
inconclusive
    no statistically significant result
CHAARTED unpublished
  NCT00268476
metastatic, hormone-sensitive prostate cancer-/-NA
suggested
  • suggested 28 % decrease in deaths (OS)
enzalutamide plus ADT
ARCHES, 2022
  NCT02677896
RCTmetastatic, hormone-sensitive prostate cancer574 / 576NA
suggested
  • suggested 34 % decrease in deaths (OS)
ENZAMET, 2019
  NCT02446405
RCTmetastatic, hormone-sensitive prostate cancerenzalutamide plus testosterone suppressionstandard nonsteroidal antiandrogen therapymen with metastatic, hormone-sensitive prostate cancer-/-NA
suggested
  • suggested 33 % decrease in deaths (OS)
versus docetaxel plus ADT
abiraterone plus docetaxel plus ADT
PEACE-1, 2022
  NCT01957436
RCTmetastatic, hormone-sensitive prostate cancerabiraterone androgen deprivation therapy with docetaxel populationandrogen deprivation therapy with docetaxel populationde novo metastatic castration-sensitive prostate cancer355 / 355NA
conclusif
  • demonstrated 25 % decrease in deaths (OS) (PE)
darolutamide plus doxetaxel plus ADT
ARASENS , 2022
  NCT02799602
RCTmetastatic, hormone-sensitive prostate cancerdarolutamide, androgen-deprivation therapy, and docetaxelandrogen-deprivation therapy, and docetaxelmetastatic, hormone-sensitive prostate cancer,651 / 655NA
conclusif
  • demonstrated 32 % decrease in deaths (OS) (PE)